November 30, 2015 6:48am
An ability to maintain or recover appreciation; can some sector’s participants make up for slips, failures and missteps?
There has been value in the short-term where consequences also lie! Subscription required: http://www.regmedinvestors.com/create-account
I say today what others won't, so you can do what others can't!
DOW futures are UP +0.2% and NASDAQ futures are UP +0.3%
Stock futures pointed to small gains on Monday, as investors returning from the Thanksgiving break get ready for central bank moves later in the week.
The week could be volatile for markets, with a policy meeting at the European Central Bank and a speech by Federal Reserve Chairwoman Janet Yellen on the docket. Friday brings the last batch of U.S. jobs numbers before the Fed’s December policy meeting and a crucial meeting of the Organization of the Petroleum Exporting Countries.
European stock markets are higher as investors gear up for a busy week of economic events, including inflation data and the European Central Bank meeting.
Asian equities closed mostly in the red as investors remained cautious following a mixed performance from Wall Street last Friday.
Data docket: The Chicago Purchasing Managers Index for November will be released at 9:45 a.m. ET, followed by pending-home sales for October at 10 a.m. ET. This week, a steady trickle of data builds to the November nonfarm payrolls report on Friday.
The RegMed sector closed POSITIVE on Friday, Wednesday, Tuesday and last Monday.
The week in review is defined by the numbers:
· Friday closed POSITIVE with 15 decliners, 23 advancers and 5 flats;
· Thursday – holiday;
· Wednesday closed POSITIVE with 12 decliners, 29 advancers and 2 flat
· Tuesday closed POSITIVE with 16 decliners, 23 advancers and 4 flats;
· Last Monday closed POSITIVE with 9 decliners, 32 advancers and 2 flats;
The inconsistency of positive and negative closes in the past weeks and pricing deviations in the stem, cell and gene therapy and regenerative medicine (SCGT&RM) sector suggests “our’ universe is NOT finished with over-reactions whether by volatility, duress or continued fluctuations!
- Sector pricing cut through some resistance levels last week;
There's more decision making needed for any sector ‘participant” position initiation or exit especially as we approach the end of the year issue of tax selling candidates;
- I’d be a seller, so I could come back – as a buyer!
Perception and reality have tended to merge …
A major shareholder is urging Northwest Biotherapeutics (NWBO) to hold an inquiry into allegations concerning financial irregularities and governance by Chairman and CEO Linda Powers.
- Neil Woodford, a U.K. fund manager well-known for investing in the biotech industry has sent a letter to the BOD of NWBO to recommend the establishment of an independent special committee to investigate the claims of financial irregularities and governance issues.
The letter was contained in a filing with the U.S. SEC.
- CEO Powers in interviews on Friday and Saturday with The Wall Street Journal denied there have been any financial irregularities between Northwest and entities related to her. She termed the allegations as “baloney.”
- She said payments for services to such entities had been cleared by NWBO’s BOD, independently audited and filed where necessary with regulators.
NWBO’s stock closed Friday's session at $4.70 with a total market capitalization of $434.8 M.
- The trading range ran $4.64 to $4.85 with 95.7 K shares traded <3 month average = 482.2 K shares>. NWBO’s stock has traded below its 50-day daily average volume of $5.00;
- NWBO’s shares have been declining through most of November;
Northwest Bio (NWB) will be feeling the effects of the SEC filing – Maintaining SELL;
Monday’s indications:
After a positive holiday-shortened week and a tepid November , which officially ends Monday; does December promise better returns for investors?
- Hedge funds have been trimming their positions amid the market volatility and uncertainty, and given their greater inclination towards smaller cap stocks than other investors, it just may be that a stronger sell-off could occur in SCGT&RM stocks.
Many SCGT&RM stocks are also dependent on retail brokers and trader/speculators which need to be motivated by event orientation to maintain any movement forward – might be a tough month other than historical trends !
If one recognizes the negatives, it is always better to comprehend the upside potential!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
